Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Day

Showing results (41-50 of 501) with videos related to

Pageof 51
Sort By:
Comprehensive Therapy|November 1, 1981
Primary inflammatory muscle diseasesR O Day, C M Pearson
British Journal of Clinical Pharmacology|June 1, 1987
Variations in response to non-steroidal anti-inflammatory drugsR O Day, P M Brooks
The Journal of Rheumatology|May 1, 1995
Toxicity of antirheumatic drugs. Toxicity Workgroup LeadersP M Brooks, R O Day
The Medical Journal of Australia|October 16, 2003
Adverse event reporting in clinical trials: room for improvementWinston S Liauw, Richard O Day
BMJ (Clinical Research Ed.)|June 13, 2013
Non-steroidal anti-inflammatory drugs (NSAIDs)Richard O Day, Garry G Graham
Drug Safety|January 27, 2007
Open-label extension studies: do they provide meaningful information on the safety of new drugs?Richard O Day, Kenneth M Williams
The Medical Journal of Australia|September 7, 1992
Cyclosporin and calcium channel blockers: an exploitable drug interaction?D M Leibbrandt, R O Day
Southern Medical Journal|November 1, 1978
Asymptomatic Bartter's syndromeG L Barbour, J O Day
Drug Safety|October 1, 1994
Risks and benefits of drugs used in the management and prevention of goutP G Conaghan, R O Day
Drugs & Aging|May 1, 1991
The problems and pitfalls of NSAID therapy in the elderly (Part II)A G Johnson, R O Day
Pageof 51

Showing results (41-50 of 501) with videos related to

Sort By:
Pageof 51
Comprehensive Therapy|November 1, 1981
Primary inflammatory muscle diseasesR O Day, C M Pearson
British Journal of Clinical Pharmacology|June 1, 1987
Variations in response to non-steroidal anti-inflammatory drugsR O Day, P M Brooks
The Journal of Rheumatology|May 1, 1995
Toxicity of antirheumatic drugs. Toxicity Workgroup LeadersP M Brooks, R O Day
The Medical Journal of Australia|October 16, 2003
Adverse event reporting in clinical trials: room for improvementWinston S Liauw, Richard O Day
BMJ (Clinical Research Ed.)|June 13, 2013
Non-steroidal anti-inflammatory drugs (NSAIDs)Richard O Day, Garry G Graham
Drug Safety|January 27, 2007
Open-label extension studies: do they provide meaningful information on the safety of new drugs?Richard O Day, Kenneth M Williams
The Medical Journal of Australia|September 7, 1992
Cyclosporin and calcium channel blockers: an exploitable drug interaction?D M Leibbrandt, R O Day
Southern Medical Journal|November 1, 1978
Asymptomatic Bartter's syndromeG L Barbour, J O Day
Drug Safety|October 1, 1994
Risks and benefits of drugs used in the management and prevention of goutP G Conaghan, R O Day
Drugs & Aging|May 1, 1991
The problems and pitfalls of NSAID therapy in the elderly (Part II)A G Johnson, R O Day
Pageof 51